According to Prime Therapeutics, only 8% to 14% of people stayed on their treatment plan after three years*
If the decision is made to re-administer the product, monitor patients for a reoccurrence of signs and symptoms of a severe hypersensitivity reaction
Your total first-year investment in personalized GLP-1 therapy with genetic optimization can be covered entirely through pre-tax dollars, reducing your net cost by your effective tax rate
Most of these symptoms peak during the first two to four weeks after each dose escalation and fade over the subsequent four to eight weeks as receptor adaptation occurs
Researchers study this blend to explore peptide signaling, cellular activity, and tissue-related pathways
Mounjaro is dual-action, meaning it targets two different-hormone receptors, GLP-1 and Gastric inhibitory polypeptide (GIP), both of which affect hunger levels and feelings of fullness